Clinical Approach to Weakness

Comprehensive Practical Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of weakness

Weakness is one of the most common and clinically significant complaints encountered in neurology, accounting for approximately 5% of all emergency department visits and representing the chief complaint in up to 13% of primary care consultations. Distinguishing true motor weakness from fatigue, malaise, or generalized debility is the critical first step in evaluation. True neuromuscular weakness affects an estimated 1 in 50 adults over their lifetime, with conditions such as stroke affecting 795,000 Americans annually and peripheral neuropathy affecting up to 8% of adults over age 55.

Definition

True weakness (paresis) is the objective reduction in muscle strength resulting from dysfunction anywhere along the motor pathway — from the cerebral cortex to the muscle fiber itself. This must be distinguished from asthenia (subjective sense of weakness without objective strength loss) and fatigue (weakness that develops or worsens with sustained effort). Complete loss of motor function is termed paralysis or plegia.

Classification by Duration

Category	Duration	Common Causes	Clinical Significance
Hyperacute	Seconds to minutes	Stroke, transient ischemic attack, seizure with postictal paresis	Neurological emergency; consider thrombolysis window
Acute	Hours to days	Guillain-Barré syndrome, acute transverse myelitis, myasthenic crisis	Requires urgent evaluation; may need intensive care monitoring
Subacute	Days to weeks	Inflammatory myopathy, chronic inflammatory demyelinating polyneuropathy, spinal cord compression	Allows time for systematic workup; treatment often immunomodulatory
Chronic	Months to years	Motor neuron disease, hereditary neuropathies, muscular dystrophies	Often progressive; focus on diagnosis and supportive care

Classification by Pattern of Distribution

Proximal versus Distal

Proximal weakness (shoulder girdle, hip flexors) suggests myopathy or neuromuscular junction disorders. Patients report difficulty climbing stairs, rising from chairs, or lifting arms overhead.

Distal weakness (hands, feet) suggests peripheral neuropathy or motor neuron disease. Patients report foot drop, difficulty with fine motor tasks, or grip weakness.

Symmetric versus Asymmetric

Symmetric weakness suggests systemic or metabolic causes, myopathies, or length-dependent neuropathies.

Asymmetric weakness suggests focal lesions (stroke, radiculopathy), multifocal processes (vasculitic neuropathy), or motor neuron disease.

Classification by Anatomical Localization

Level	Pattern	Associated Features	Examples
Upper Motor Neuron	Pyramidal distribution (extensors in upper limb, flexors in lower limb)	Spasticity, hyperreflexia, Babinski sign, no significant atrophy early	Stroke, multiple sclerosis, spinal cord lesion
Lower Motor Neuron	Follows nerve root, plexus, or peripheral nerve distribution	Flaccidity, hyporeflexia, atrophy, fasciculations	Radiculopathy, peripheral neuropathy, motor neuron disease
Neuromuscular Junction	Fatigable weakness; ocular, bulbar, or proximal limb	Fluctuating symptoms, ptosis, diplopia, no sensory loss	Myasthenia gravis, Lambert-Eaton syndrome
Muscle	Proximal > distal; symmetric	No sensory loss, reflexes preserved until late, possible myalgia	Inflammatory myopathy, muscular dystrophy

Special Patterns and Their Significance

Pattern	Description	Suggests
Hemiparesis	Weakness of face, arm, and leg on one side	Contralateral hemispheric lesion (stroke, tumor, demyelination)
Paraparesis	Weakness of both lower extremities	Spinal cord lesion, bilateral cerebral lesions (parasagittal), cauda equina syndrome
Quadriparesis	Weakness of all four limbs	High cervical cord lesion, brainstem lesion, diffuse peripheral process (Guillain-Barré syndrome)
Monoparesis	Weakness confined to one limb	Cortical lesion, plexopathy, mononeuropathy, radiculopathy
Bulbar weakness	Weakness of speech, swallowing, facial muscles	Brainstem lesion, motor neuron disease, myasthenia gravis, inflammatory myopathy
Fatigable weakness	Strength declines with repetitive use; recovers with rest	Neuromuscular junction disorder (myasthenia gravis)

The Localization Imperative: The single most important task when evaluating weakness is anatomical localization. Before considering specific diagnoses, determine whether the lesion is in the: (1) Upper motor neuron (brain or spinal cord), (2) Lower motor neuron (anterior horn cell, nerve root, plexus, peripheral nerve), (3) Neuromuscular junction, or (4) Muscle. This localization drives the entire diagnostic workup.

2. Pathophysiology and Mechanisms

Understanding the underlying mechanisms of weakness

Voluntary movement requires the coordinated function of a complex motor pathway extending from the cerebral cortex to the muscle fiber. Weakness results from disruption at any level of this pathway. Understanding the anatomy and physiology of each component is essential for localizing the lesion and guiding investigation. The motor system can be conceptualized as a two-neuron pathway: the upper motor neuron (from cortex to anterior horn) and the lower motor neuron (from anterior horn to muscle), connected to muscle via the neuromuscular junction.

The Motor Pathway

Component	Structure	Function
Primary Motor Cortex	Precentral gyrus (Brodmann area 4)	Initiation of voluntary movement; somatotopic organization (motor homunculus)
Corticospinal Tract	Corona radiata → internal capsule → cerebral peduncle → medullary pyramid	Transmission of motor commands; 85% decussate at pyramidal decussation
Spinal Cord	Lateral corticospinal tract → anterior horn	Relay of upper motor neuron signals to lower motor neurons
Anterior Horn Cell	Gray matter of spinal cord ventral horn	Lower motor neuron cell body; final common pathway integration
Peripheral Nerve	Ventral root → plexus → peripheral nerve	Conduction of action potentials to neuromuscular junction
Neuromuscular Junction	Presynaptic terminal, synaptic cleft, postsynaptic membrane	Chemical transmission via acetylcholine release and receptor binding
Muscle Fiber	Sarcolemma, T-tubules, sarcoplasmic reticulum, myofibrils	Excitation-contraction coupling; force generation via actin-myosin interaction

Upper Motor Neuron versus Lower Motor Neuron Lesions

Upper Motor Neuron (UMN) Features

Pathophysiology: Loss of descending inhibition leads to release of spinal reflex arcs

Tone: Increased (spasticity) — velocity-dependent resistance

Reflexes: Hyperreflexia with clonus

Babinski sign: Present (upgoing plantar response)

Atrophy: Minimal (disuse only, develops late)

Fasciculations: Absent

Distribution: Pyramidal pattern (flexors weak in arm, extensors weak in leg)

Lower Motor Neuron (LMN) Features

Pathophysiology: Loss of trophic support and denervation of muscle fibers

Tone: Decreased (flaccidity)

Reflexes: Hyporeflexia or areflexia

Babinski sign: Absent (flexor or no response)

Atrophy: Prominent and early

Fasciculations: Present (spontaneous motor unit discharges)

Distribution: Follows myotomal, plexus, or peripheral nerve pattern

Mechanisms of Weakness by Anatomical Level

Level	Mechanism	Clinical Implication
Cortex/Subcortical	Ischemia, hemorrhage, demyelination, mass effect disrupting motor cortex or descending fibers	Contralateral weakness; face and arm often more affected than leg in middle cerebral artery stroke
Brainstem	Infarction affecting corticospinal tract; often with cranial nerve involvement	Crossed deficits (ipsilateral cranial nerve, contralateral limb weakness)
Spinal Cord	Compression, inflammation, ischemia, demyelination affecting corticospinal tracts	Level determines pattern; cervical affects all four limbs, thoracic spares arms
Anterior Horn Cell	Degeneration (motor neuron disease), viral infection (polio), autoimmune attack	Mixed UMN and LMN signs in amyotrophic lateral sclerosis; pure LMN in spinal muscular atrophy
Nerve Root	Compression (disc herniation), inflammation, infiltration	Dermatomal sensory loss with myotomal weakness; radicular pain common
Plexus	Trauma, compression, inflammation (plexitis), infiltration (tumor, radiation)	Multiple nerve root and peripheral nerve distributions affected; complex pattern
Peripheral Nerve	Demyelination (conduction block), axonal degeneration (Wallerian), compression	Demyelinating causes conduction slowing; axonal causes denervation changes on electromyography
Neuromuscular Junction	Autoantibodies against acetylcholine receptors (myasthenia gravis) or presynaptic calcium channels (Lambert-Eaton)	Fatigable weakness; improves with rest or acetylcholinesterase inhibitors in myasthenia gravis
Muscle	Inflammatory destruction, genetic defects in structural proteins, metabolic dysfunction	Proximal weakness predominates; creatine kinase elevation common; no sensory involvement

Neuromuscular Junction Transmission

Normal Transmission

Step 1: Action potential arrives at presynaptic terminal

Step 2: Calcium influx triggers acetylcholine vesicle release

Step 3: Acetylcholine binds postsynaptic receptors

Step 4: End-plate potential triggers muscle action potential

Myasthenia Gravis

Defect: Autoantibodies against acetylcholine receptors

Result: Reduced receptor density and impaired transmission

Clinical effect: Fatigable weakness worsening with repeated use

Safety factor: Reduced; threshold for failure lowered

Lambert-Eaton Syndrome

Defect: Autoantibodies against presynaptic voltage-gated calcium channels

Result: Reduced acetylcholine release

Clinical effect: Weakness that may improve briefly with exercise (facilitation)

Association: Small cell lung cancer in 50-60% of cases

Muscle Fiber Pathophysiology

Category	Mechanism	Examples	Key Feature
Inflammatory	Immune-mediated destruction of muscle fibers	Polymyositis, dermatomyositis, inclusion body myositis	Elevated creatine kinase; responds to immunosuppression (except inclusion body myositis)
Dystrophic	Genetic defects in structural proteins (dystrophin, sarcoglycans)	Duchenne muscular dystrophy, limb-girdle muscular dystrophy	Progressive; onset often in childhood; characteristic patterns
Metabolic	Enzyme deficiencies affecting energy metabolism	McArdle disease (myophosphorylase deficiency), mitochondrial myopathies	Exercise intolerance; may have episodic weakness or rhabdomyolysis
Toxic/Drug-induced	Direct myotoxicity or immune-mediated damage	Statin myopathy, alcohol, corticosteroids	Temporal relationship to drug exposure; may resolve with discontinuation
Endocrine	Hormonal effects on muscle metabolism and protein synthesis	Hypothyroid myopathy, Cushing syndrome, hyperparathyroidism	Reversible with treatment of underlying endocrine disorder

Often Overlooked: Motor Neuron Disease Has Mixed Signs

Amyotrophic lateral sclerosis (ALS) uniquely affects both upper and lower motor neurons simultaneously. Finding both upper motor neuron signs (hyperreflexia, spasticity, Babinski) and lower motor neuron signs (atrophy, fasciculations) in the same limb is highly suggestive of motor neuron disease. This combination should not occur in isolated upper or lower motor neuron lesions and should prompt urgent referral.

The Sensory Clue: When Weakness Has Sensory Loss

Key Principle: The presence or absence of sensory involvement helps localize the lesion:

Weakness WITH sensory loss: Suggests lesion involves sensory pathways — brain, spinal cord, nerve root, plexus, or peripheral nerve
Weakness WITHOUT sensory loss: Suggests pure motor pathology — motor cortex, anterior horn cell, neuromuscular junction, or muscle
Exception: Some peripheral neuropathies (pure motor neuropathies like multifocal motor neuropathy) spare sensory fibers

3. History Taking

A comprehensive approach to eliciting the weakness history

Red Flags — Require Urgent Evaluation

Hyperacute onset (seconds to minutes) — Stroke until proven otherwise
Rapidly ascending weakness — Guillain-Barré syndrome; monitor respiratory function
Respiratory muscle involvement — Dyspnea, orthopnea, weak cough; may need ventilatory support
Bulbar symptoms — Dysarthria, dysphagia, drooling; aspiration risk

Bladder or bowel dysfunction with weakness — Spinal cord compression; MRI within hours
Weakness with severe pain at specific spinal level — Epidural abscess, metastatic cord compression
Bilateral leg weakness with sensory level — Transverse myelitis, cord compression
Ptosis with diplopia and progressive weakness — Myasthenic crisis; risk of respiratory failure

Systematic History: The “WEAKNESS” Approach

Use the mnemonic “WEAKNESS” to ensure comprehensive history taking:

W — When and How: Onset (sudden, gradual, stepwise), duration, progression pattern
E — Extent and Distribution: Which muscles? Proximal or distal? Symmetric or asymmetric? Focal or diffuse?
A — Associated Symptoms: Sensory changes, pain, fatigue, diplopia, dysphagia, breathing difficulty, bladder/bowel
K — Key Functional Impact: Climbing stairs, rising from chair, lifting arms, grip strength, walking, falls
N — Neurological History: Prior episodes, known neurological conditions, family history of neuromuscular disease
E — Exacerbating and Relieving Factors: Exercise effect (fatigue versus facilitation), rest, heat, cold, time of day
S — Systemic Features: Fever, weight loss, rash, joint pain, malignancy history, recent infections
S — Substances and Medications: Statins, steroids, alcohol, drugs of abuse, recent immunizations

Targeted Questions by Suspected Cause

Suspected Cause	Key Features	Ask This Question
Stroke	Sudden onset, unilateral, vascular risk factors	“Exactly what were you doing when it started? Did it come on all at once or build up?”
Guillain-Barré syndrome	Ascending paralysis, preceding infection	“Did you have a cold, flu, or diarrheal illness in the 2-4 weeks before this started?”
Myasthenia gravis	Fatigable weakness, ocular and bulbar symptoms	“Is your weakness worse at the end of the day? Do your eyelids droop or do you see double?”
Inflammatory myopathy	Proximal weakness, difficulty with overhead activities	“Do you have trouble washing your hair, getting up from a low chair, or climbing stairs?”
Motor neuron disease (amyotrophic lateral sclerosis)	Progressive, mixed upper and lower motor neuron signs	“Have you noticed muscle twitching under your skin? Any trouble with speech or swallowing?”
Spinal cord compression	Back pain, sensory level, sphincter dysfunction	“Do you have back pain? Any numbness below a certain level? Trouble with bladder or bowels?”
Peripheral neuropathy	Distal, symmetric, sensory symptoms common	“Did it start in your feet and work upward? Do you have numbness or tingling?”
Radiculopathy	Dermatomal pattern, radiating pain	“Does the weakness follow pain that shoots down your arm or leg?”
Lambert-Eaton myasthenic syndrome	Proximal weakness, autonomic symptoms, improves briefly with use	“Does your strength improve after a few seconds of exercise? Do you have dry mouth or constipation?”
Periodic paralysis	Episodic weakness, triggered by carbohydrates or rest after exercise	“Do you have episodes of weakness that come and go? Does eating carbs or resting after exercise trigger it?”

Distinguishing True Weakness from Mimics

Complaint	True Weakness	Fatigue/Asthenia	Key Differentiating Question
“I feel weak”	Cannot perform specific tasks despite trying	Tired, lacks energy to attempt tasks	“Can you lift your arm, or do you just feel too tired to try?”
“My legs give out”	Objective leg weakness on examination	Pain-limited, deconditioning, joint instability	“Do your legs actually buckle, or do you stop because of pain or tiredness?”
“I can’t grip”	Reduced grip strength measurably	Pain in hand, arthritis limiting grip	“Is it that you can’t squeeze hard, or that squeezing hurts?”

Medication and Substance History

Medications That Cause Weakness

Statins — Myopathy (common), rhabdomyolysis (rare); risk increased with high dose, drug interactions
Corticosteroids — Steroid myopathy; proximal weakness with prolonged use
Colchicine — Myopathy and neuropathy, especially with renal impairment
Antiretrovirals (zidovudine) — Mitochondrial myopathy
Hydroxychloroquine — Myopathy and cardiomyopathy with prolonged use
Amiodarone — Peripheral neuropathy (axonal)
Immune checkpoint inhibitors — Myositis, myasthenia gravis, neuropathy
Fluoroquinolones — Tendinopathy, may exacerbate myasthenia gravis

Social and Exposure History

Alcohol: Chronic myopathy, peripheral neuropathy; assess quantity and duration
Illicit drugs: Cocaine (rhabdomyolysis), heroin (compressive neuropathy)
Occupation: Lead exposure (motor neuropathy), repetitive strain (entrapment)
Travel: Poliomyelitis (endemic areas), tick paralysis, tropical infections
Dietary history: Vitamin B12 deficiency (vegans), thiamine deficiency (alcoholics)
Recent infections: Guillain-Barré syndrome trigger (Campylobacter, cytomegalovirus, Epstein-Barr virus)
Immunizations: Rare trigger for Guillain-Barré syndrome

Family History: Key Conditions to Ask About

Hereditary Neuromuscular Diseases

Many causes of weakness are genetic. Ask specifically about:

Muscular dystrophy — “Did anyone in your family use a wheelchair or have muscle wasting?”
Charcot-Marie-Tooth disease — “Does anyone have high arches, hammer toes, or weak ankles?”
Myotonic dystrophy — “Does anyone have difficulty releasing their grip, cataracts at a young age, or heart rhythm problems?”
Hereditary neuropathies — “Did any relatives have numbness or weakness in their feet requiring braces?”
Periodic paralysis — “Does anyone have episodes of sudden paralysis?”

4. Physical Examination

A systematic neurological approach for weakness

Systematic Framework: The neurological examination for weakness follows a structured approach: General inspection → Vital signs → Cranial nerves → Motor examination → Sensory examination → Reflexes → Coordination → Gait. The goal is to localize the lesion anatomically before considering specific diagnoses.

General Inspection

Body habitus: Cushingoid features (steroid myopathy), cachexia (malignancy, motor neuron disease)
Posture and positioning: Asymmetric posture, dropped head (neck extensor weakness), wrist or foot drop
Muscle bulk: Atrophy (lower motor neuron lesion, disuse), pseudohypertrophy (muscular dystrophy)
Fasciculations: Visible muscle twitching at rest (lower motor neuron pathology, especially motor neuron disease)
Skin: Heliotrope rash, Gottron papules (dermatomyositis), café-au-lait spots (neurofibromatosis)
Assistive devices: Braces, wheelchair, walking aids indicating chronicity and severity

Vital Signs

Vital Sign	What to Look For	Clinical Significance
Respiratory Rate and Pattern	Tachypnea, use of accessory muscles, paradoxical breathing	Respiratory muscle weakness (diaphragm, intercostals); may need urgent ventilatory support
Oxygen Saturation	Hypoxemia, especially when supine	Late sign of respiratory muscle failure; check arterial blood gas if concerned
Blood Pressure	Orthostatic hypotension, labile blood pressure	Autonomic dysfunction (Guillain-Barré syndrome, Lambert-Eaton syndrome, diabetic neuropathy)
Heart Rate	Bradycardia or tachycardia, arrhythmia	Autonomic involvement; cardiac monitoring needed in Guillain-Barré syndrome
Temperature	Fever	Infection (abscess, meningitis), inflammatory process; heat worsens myasthenia gravis

Critical: Bedside Respiratory Assessment

In neuromuscular weakness, respiratory failure can occur rapidly. Assess:

Single breath count: Ask patient to take a deep breath and count as high as possible — less than 20 suggests reduced vital capacity
Neck flexion strength: Correlates with diaphragm strength; if weak, respiratory compromise likely
Forced vital capacity (FVC): Measure serially; FVC less than 20 mL/kg or falling more than 30% indicates impending failure
Negative inspiratory force (NIF): Weaker than -30 cmH2O suggests need for ventilatory support

Cranial Nerve Examination

Cranial Nerve	Test	Abnormality and Significance
II (Optic)	Visual acuity, visual fields, fundoscopy	Papilledema (raised intracranial pressure), optic atrophy (multiple sclerosis)
III, IV, VI (Oculomotor, Trochlear, Abducens)	Eye movements, pupil responses	Diplopia, ptosis (myasthenia gravis, third nerve palsy); fatigable ptosis pathognomonic for myasthenia
V (Trigeminal)	Facial sensation, jaw strength, jaw jerk	Brisk jaw jerk (upper motor neuron lesion above pons)
VII (Facial)	Facial symmetry, eye closure, smile	Upper motor neuron pattern spares forehead; lower motor neuron affects entire hemiface
IX, X (Glossopharyngeal, Vagus)	Palate elevation, gag reflex, voice quality	Bulbar weakness (dysarthria, dysphagia, nasal voice); motor neuron disease, myasthenia gravis
XI (Accessory)	Shoulder shrug, head turning	Trapezius and sternocleidomastoid weakness
XII (Hypoglossal)	Tongue protrusion, bulk, fasciculations	Tongue atrophy and fasciculations highly suggestive of motor neuron disease

Motor Examination

Muscle Tone

Increased Tone

Spasticity: Velocity-dependent; “clasp-knife” quality; upper motor neuron lesion

Rigidity: Velocity-independent; “lead-pipe” or “cogwheel”; extrapyramidal (not true weakness)

Decreased Tone

Flaccidity: Reduced resistance to passive movement; lower motor neuron lesion, acute upper motor neuron lesion (spinal shock), cerebellar lesion

Muscle Strength Testing: Medical Research Council (MRC) Scale

Grade	Description	Clinical Interpretation
5	Normal power against full resistance	No weakness
4	Movement against resistance but reduced	Mild weakness (4+, 4, 4- may be used for gradation)
3	Movement against gravity but not resistance	Moderate weakness
2	Movement with gravity eliminated	Severe weakness
1	Flicker of contraction visible or palpable	Trace movement only
0	No contraction	Complete paralysis

Key Muscle Groups to Test

Upper Limb

Shoulder abduction (C5): Deltoid
Elbow flexion (C5-C6): Biceps
Elbow extension (C7): Triceps
Wrist extension (C6-C7): Wrist extensors
Finger extension (C7): Finger extensors
Finger abduction (T1): First dorsal interosseous
Thumb abduction (T1): Abductor pollicis brevis

Lower Limb

Hip flexion (L1-L2): Iliopsoas
Hip extension (L5-S1): Gluteus maximus
Knee extension (L3-L4): Quadriceps
Knee flexion (L5-S1): Hamstrings
Ankle dorsiflexion (L4-L5): Tibialis anterior
Ankle plantarflexion (S1-S2): Gastrocnemius
Great toe extension (L5): Extensor hallucis longus

Deep Tendon Reflexes

Reflex	Root Level	Hyperreflexia Suggests	Hyporeflexia Suggests
Biceps	C5-C6	Upper motor neuron lesion above C5	C5-C6 radiculopathy, peripheral neuropathy
Triceps	C7	Upper motor neuron lesion above C7	C7 radiculopathy
Brachioradialis	C5-C6	Upper motor neuron lesion above C5	C5-C6 radiculopathy
Knee (patellar)	L3-L4	Upper motor neuron lesion above L3	L3-L4 radiculopathy, femoral neuropathy
Ankle (Achilles)	S1	Upper motor neuron lesion above S1	S1 radiculopathy, peripheral neuropathy (often first lost)

Pathological Reflexes

Babinski sign (extensor plantar response): Upgoing great toe with fanning of other toes on stroking lateral sole; indicates upper motor neuron lesion
Hoffman sign: Flexion of thumb and index finger when flicking middle finger; suggests cervical cord or upper motor neuron pathology
Clonus: Sustained rhythmic contractions (more than 3 beats) with quick stretch; indicates upper motor neuron lesion

Sensory Examination

Why Test Sensation in Weakness?

The pattern of sensory involvement helps localize the lesion:

No sensory loss: Pure motor pathology (anterior horn cell, neuromuscular junction, muscle)
Dermatomal sensory loss: Nerve root lesion
Peripheral nerve distribution: Mononeuropathy or mononeuritis multiplex
Stocking-glove pattern: Length-dependent polyneuropathy
Sensory level: Spinal cord lesion (test for level with pinprick)
Hemisensory loss: Contralateral thalamic or cortical lesion

Coordination and Gait

Coordination Tests

Finger-nose-finger: Cerebellar dysfunction causes intention tremor and dysmetria

Heel-shin test: Cerebellar ataxia in lower limbs

Rapid alternating movements: Dysdiadochokinesia in cerebellar lesions

Note: Weakness itself can impair coordination; distinguish from true cerebellar signs

Gait Assessment

Hemiplegic gait: Circumduction of stiff leg (stroke)

Spastic gait: Stiff, scissoring legs (bilateral upper motor neuron)

Steppage gait: High stepping to clear dropped foot (peroneal neuropathy, L5 radiculopathy)

Waddling gait: Trunk sway with hip weakness (myopathy)

Trendelenburg: Pelvis drops on unsupported side (hip abductor weakness)

Functional Tests for Weakness

Test	How to Perform	What It Assesses
Gower sign	Ask patient to rise from floor	Uses hands to “climb up” thighs; indicates proximal weakness (hip extensors)
Chair rise	Rise from seated without using arms	Proximal leg weakness (quadriceps, hip flexors)
Heel and toe walking	Walk on heels, then on toes	Heel walk tests dorsiflexors (L4-L5); toe walk tests plantarflexors (S1)
Arm elevation test	Hold arms outstretched, eyes closed	Pronator drift indicates upper motor neuron lesion; downward drift indicates weakness
Sustained upgaze	Look up for 60 seconds	Fatigable ptosis develops in myasthenia gravis
Repeated squatting	Squat and stand 10 times	Fatigable weakness in neuromuscular junction disorders

Expected Findings by Etiology

Condition	Tone	Reflexes	Distribution	Other Key Findings
Stroke (hemispheric)	Increased (after acute phase)	Hyperreflexia, Babinski	Hemiparesis, face and arm often more than leg	Hemisensory loss, aphasia, neglect possible
Spinal cord lesion	Increased below level	Hyperreflexia below, may be absent at level	Paraparesis or quadriparesis with sensory level	Bladder dysfunction, sensory level on trunk
Motor neuron disease	Mixed (spastic and flaccid)	Hyperreflexia despite atrophy	Asymmetric, multisegmental	Fasciculations, tongue atrophy, bulbar signs
Guillain-Barré syndrome	Decreased (flaccid)	Areflexia	Ascending, symmetric	Sensory symptoms, facial weakness, autonomic instability
Myasthenia gravis	Normal	Normal	Ocular, bulbar, proximal; fatigable	Ptosis, diplopia, normal sensation, improves with rest
Inflammatory myopathy	Normal or slightly decreased	Normal or mildly reduced late	Proximal, symmetric	No sensory loss, possible rash, dysphagia
Peripheral neuropathy	Decreased	Hyporeflexia (ankle lost first)	Distal, symmetric, length-dependent	Stocking-glove sensory loss, foot drop

Important Teaching Point

The examination may be normal in early or mild disease! Many significant conditions — including early motor neuron disease, myasthenia gravis between episodes, and mild inflammatory myopathy — may have subtle or even normal examination findings. A normal neurological examination does not exclude neuromuscular disease. Serial examinations and specialized testing (electromyography, nerve conduction studies, laboratory tests) are often required to confirm the diagnosis.

5. Differential Diagnosis

Systematic approach organized by probability, duration, and anatomical localization

Acute Weakness (Hours to Days)

Probability	Condition	Key Features	Red Flags
COMMON	Stroke (ischemic or hemorrhagic)	Sudden onset, unilateral, vascular risk factors, associated cortical signs	Within thrombolysis window; deteriorating level of consciousness
COMMON	Transient ischemic attack	Sudden onset, resolves within 24 hours (usually less than 1 hour), focal deficits	High early stroke risk; requires urgent evaluation
COMMON	Compressive radiculopathy (disc herniation)	Radicular pain, dermatomal sensory loss, single myotome weakness	Cauda equina syndrome (bilateral, bladder involvement)
LESS COMMON	Guillain-Barré syndrome	Ascending symmetric weakness, areflexia, preceding infection 1-4 weeks prior	Rapid progression, respiratory compromise, autonomic instability
LESS COMMON	Myasthenic crisis	Known myasthenia gravis, infection or medication trigger, bulbar and respiratory weakness	Respiratory failure imminent; requires intensive care monitoring
LESS COMMON	Acute transverse myelitis	Bilateral weakness with sensory level, bladder dysfunction, back pain	Rapid progression; may indicate spinal cord compression
LESS COMMON	Spinal cord compression (malignant, abscess)	Back pain at specific level, progressive paraparesis, sphincter dysfunction	Oncologic or surgical emergency; MRI within hours
UNCOMMON BUT SERIOUS	Hypokalemic periodic paralysis	Episodic flaccid paralysis, triggered by carbohydrates or rest after exercise	Severe hypokalemia may cause arrhythmias
UNCOMMON BUT SERIOUS	Botulism	Descending paralysis, bulbar onset, pupil involvement, food exposure	Respiratory paralysis; notify public health
UNCOMMON BUT SERIOUS	Tick paralysis	Ascending paralysis, recent outdoor exposure, attached tick found	Rapid recovery after tick removal; search thoroughly

Subacute Weakness (Days to Weeks)

Clinical Approach to Subacute Weakness:

Step 1: Determine if upper or lower motor neuron pattern (or mixed)
Step 2: Assess distribution — proximal versus distal, symmetric versus asymmetric
Step 3: Check for sensory involvement — present suggests nerve/root/cord; absent suggests anterior horn, neuromuscular junction, or muscle
Step 4: Look for systemic features — rash, weight loss, fever suggesting inflammatory or malignant cause

Probability	Condition	Typical Presentation	Key Distinguishing Features
COMMON	Inflammatory myopathy (polymyositis, dermatomyositis)	Proximal weakness over weeks, difficulty climbing stairs, rising from chair	Elevated creatine kinase, rash in dermatomyositis, no sensory loss
COMMON	Cervical or lumbar radiculopathy	Pain radiating in dermatomal pattern, weakness in single myotome	Positive straight leg raise or Spurling test; MRI shows disc/foraminal disease
LESS COMMON	Chronic inflammatory demyelinating polyneuropathy	Progressive symmetric weakness over more than 8 weeks, proximal and distal	Areflexia, elevated cerebrospinal fluid protein, demyelinating nerve conduction studies
LESS COMMON	Myasthenia gravis (new diagnosis)	Fatigable weakness, ptosis, diplopia, bulbar symptoms	Fluctuating symptoms, worse with activity, positive antibodies
LESS COMMON	Multiple sclerosis (spinal cord relapse)	Subacute myelopathy, often with sensory symptoms, prior episodes	Young adult, relapsing course, MRI shows demyelinating lesions
LESS COMMON	Brachial or lumbosacral plexopathy	Severe pain followed by weakness in multiple nerve distributions	May be idiopathic (neuralgic amyotrophy) or diabetic
UNCOMMON BUT SERIOUS	Lambert-Eaton myasthenic syndrome	Proximal weakness, autonomic symptoms (dry mouth), improves briefly with exercise	Associated with small cell lung cancer in 50-60%; check voltage-gated calcium channel antibodies
UNCOMMON BUT SERIOUS	Paraneoplastic syndrome	Subacute weakness with systemic symptoms, weight loss	Search for occult malignancy; check paraneoplastic antibody panel

Chronic Weakness (Months to Years)

Probability	Condition	Approximate Frequency	Key Distinguishing Features
COMMON	Diabetic polyneuropathy	Most common cause of peripheral neuropathy in developed countries	Length-dependent, sensory predominant, distal weakness late, diabetes history
COMMON	Chronic radiculopathy with myelopathy (cervical spondylotic myelopathy)	Common in adults over 50	Gait disturbance, hand clumsiness, mixed upper and lower motor neuron signs in upper limbs
COMMON	Inclusion body myositis	Most common acquired myopathy in patients over 50	Asymmetric, finger flexors and quadriceps affected early, poor response to immunosuppression
LESS COMMON	Amyotrophic lateral sclerosis (motor neuron disease)	Incidence 2-3 per 100,000	Progressive, mixed upper and lower motor neuron signs, no sensory loss, fasciculations
LESS COMMON	Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy)	Most common inherited neuropathy; 1 in 2,500	Distal weakness, pes cavus, hammer toes, family history, onset in childhood or adolescence
LESS COMMON	Limb-girdle muscular dystrophy	Variable; multiple genetic subtypes	Proximal weakness, elevated creatine kinase, onset typically in teens to young adulthood
LESS COMMON	Myotonic dystrophy	Most common adult muscular dystrophy	Distal weakness, myotonia (delayed relaxation), cataracts, cardiac conduction defects, family history
UNCOMMON	Spinal muscular atrophy (adult-onset)	Rare; 1 in 10,000	Symmetric proximal weakness, lower motor neuron signs only, no sensory loss
UNCOMMON	Kennedy disease (spinal bulbar muscular atrophy)	Rare; X-linked	Males only, bulbar weakness, gynecomastia, sensory neuropathy, slow progression

Anatomical Approach to Weakness

Upper Motor Neuron (Brain/Spinal Cord)

Stroke

Multiple sclerosis

Spinal cord compression

Transverse myelitis

Cervical spondylotic myelopathy

Primary lateral sclerosis

Lower Motor Neuron (Anterior Horn to Nerve)

Motor neuron disease (amyotrophic lateral sclerosis)

Spinal muscular atrophy

Poliomyelitis / Post-polio syndrome

Radiculopathy

Plexopathy

Peripheral neuropathy

Neuromuscular Junction

Myasthenia gravis

Lambert-Eaton myasthenic syndrome

Botulism

Organophosphate poisoning

Congenital myasthenic syndromes

Drug-induced (aminoglycosides, magnesium)

Muscle

Inflammatory myopathy (polymyositis, dermatomyositis)

Inclusion body myositis

Muscular dystrophies

Metabolic myopathies

Toxic/drug-induced myopathy

Endocrine myopathy

Drug-Induced Weakness

Drug or Drug Class	Mechanism	Characteristics	Time to Resolution After Stopping
Statins (HMG-CoA reductase inhibitors)	Direct myotoxicity; rarely immune-mediated necrotizing myopathy	Proximal weakness, myalgia, elevated creatine kinase; risk increases with dose and interacting drugs	Weeks to months; immune-mediated form may persist
Corticosteroids	Type II fiber atrophy; altered protein metabolism	Proximal weakness, especially hip flexors; normal creatine kinase; dose and duration dependent	Weeks to months after dose reduction
Colchicine	Disruption of microtubules; vacuolar myopathy	Proximal myopathy with neuropathy; risk increased in renal impairment	Weeks to months
Hydroxychloroquine	Lysosomal dysfunction; vacuolar myopathy	Proximal weakness after prolonged use (years); may affect heart	Months; may be irreversible
Zidovudine (AZT)	Mitochondrial toxicity	Proximal myopathy, elevated creatine kinase, ragged red fibers on biopsy	Weeks to months
Immune checkpoint inhibitors	Immune-mediated myositis, myasthenia gravis	Can be severe and rapid; may coexist with myocarditis	Variable; may require immunosuppression
Aminoglycosides	Neuromuscular junction blockade (presynaptic)	Can precipitate or worsen myasthenic crisis	Days (after drug clearance)
Fluoroquinolones	Mechanism unclear; may exacerbate myasthenia gravis	Tendinopathy common; myasthenia exacerbation rare but serious	Days to weeks
Alcohol (chronic)	Direct myotoxicity; nutritional deficiency	Acute rhabdomyolysis or chronic proximal myopathy; often with neuropathy	Months with abstinence and nutrition
Amiodarone	Axonal neuropathy; occasionally myopathy	Peripheral neuropathy more common; proximal weakness less common	Months (long half-life)

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
Sudden hemiparesis with facial droop	Stroke	Activate stroke protocol; CT head immediately
Ascending weakness with areflexia after viral illness	Guillain-Barré syndrome	Admit; monitor respiratory function; lumbar puncture
Fatigable ptosis and diplopia worse in evening	Myasthenia gravis	Acetylcholine receptor antibodies; ice pack test; CT chest for thymoma
Proximal weakness with heliotrope rash	Dermatomyositis	Creatine kinase; EMG; muscle biopsy; malignancy screening
Finger flexor and quadriceps weakness in elderly patient	Inclusion body myositis	Creatine kinase (may be mildly elevated); EMG; muscle biopsy
Mixed upper and lower motor neuron signs with fasciculations	Amyotrophic lateral sclerosis	EMG/nerve conduction studies; MRI to exclude structural causes
Weakness with sensory level and bladder symptoms	Spinal cord lesion (compression, myelitis)	Urgent MRI spine; if compression, neurosurgical consultation
Distal weakness with pes cavus and hammer toes	Charcot-Marie-Tooth disease	Nerve conduction studies; genetic testing
Proximal weakness with dry mouth, improves with exercise	Lambert-Eaton myasthenic syndrome	Voltage-gated calcium channel antibodies; CT chest for lung cancer
Weakness in patient on statin with elevated creatine kinase	Statin-induced myopathy	Stop statin; monitor creatine kinase; consider immune-mediated form if persistent
Radicular pain followed by weakness in arm	Cervical radiculopathy or brachial plexopathy	MRI cervical spine; EMG if plexopathy suspected
Descending paralysis with bulbar onset and pupil changes	Botulism	Contact public health; antitoxin; supportive care

6. Diagnostic Investigations

A stepwise, localization-guided approach to investigating weakness

Baseline Investigations for All Patients with Unexplained Weakness

Investigation	Purpose	What to Look For	Practical Points
Complete blood count	Screen for anemia, infection, malignancy	Anemia (fatigue mimic); elevated white cells (infection); macrocytosis (B12 deficiency)	Anemia causes fatigue, not true weakness; but may coexist
Electrolytes (sodium, potassium, calcium, magnesium, phosphate)	Identify metabolic causes of weakness	Hypokalemia (periodic paralysis, proximal weakness); hypercalcemia; hypomagnesemia	Check urgently if acute weakness; hypokalemia can be life-threatening
Creatine kinase (CK)	Detect muscle damage	Elevated in myopathy, rhabdomyolysis; mildly elevated in motor neuron disease	Normal CK does not exclude myopathy; very high (more than 10× normal) suggests myositis or rhabdomyolysis
Thyroid function tests (TSH, free T4)	Screen for thyroid-related weakness	Hypothyroidism (proximal weakness, elevated CK); hyperthyroidism (proximal weakness, normal or low CK)	Reversible cause; always check in unexplained proximal weakness
Renal function (creatinine, urea)	Assess for uremic neuropathy; drug clearance	Elevated creatinine may indicate rhabdomyolysis or chronic kidney disease	Important for drug dosing; colchicine toxicity increased in renal failure
Liver function tests	Screen for hepatic causes; baseline for medications	Elevated transaminases may be from muscle (AST, ALT can be elevated in myopathy)	If transaminases elevated, check CK to differentiate liver from muscle source
Glucose (fasting) or HbA1c	Screen for diabetes	Diabetic neuropathy; diabetic amyotrophy	Most common cause of peripheral neuropathy in developed countries
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)	Screen for inflammatory process	Elevated in inflammatory myopathy, vasculitis, infection	Non-specific; helps support inflammatory etiology
Vitamin B12	Screen for deficiency causing neuropathy or myelopathy	Low B12 causes subacute combined degeneration (myelopathy and neuropathy)	Check methylmalonic acid if B12 borderline; treat empirically if deficiency suspected

Targeted Investigations by Suspected Etiology

If Suspecting Upper Motor Neuron Lesion (Brain or Spinal Cord)

First-Line Tests

CT head (non-contrast): Immediate if acute stroke suspected; detects hemorrhage within minutes
MRI brain with diffusion-weighted imaging: Gold standard for acute ischemic stroke; detects infarct within minutes of onset
MRI spine (with contrast if indicated): Compressive lesion, myelitis, demyelination; level guided by clinical examination

Second-Line Tests

CT angiography or MR angiography: Vascular lesion, dissection, stenosis
Lumbar puncture: Multiple sclerosis (oligoclonal bands), transverse myelitis, infection
Visual evoked potentials: Subclinical optic neuritis supporting multiple sclerosis diagnosis

If Suspecting Lower Motor Neuron Lesion (Anterior Horn, Root, Plexus, Nerve)

First-Line Tests

Nerve conduction studies (NCS): Distinguishes demyelinating from axonal neuropathy; localizes entrapment
Electromyography (EMG): Detects denervation (fibrillations, positive sharp waves); neurogenic versus myopathic pattern
MRI spine: Radiculopathy (disc herniation, foraminal stenosis); plexopathy

Second-Line Tests

Lumbar puncture: Guillain-Barré syndrome (albuminocytologic dissociation); chronic inflammatory demyelinating polyneuropathy
Anti-ganglioside antibodies: GM1 (multifocal motor neuropathy); GQ1b (Miller Fisher syndrome)
Genetic testing: Charcot-Marie-Tooth disease; hereditary neuropathies
Nerve biopsy: Vasculitic neuropathy; amyloidosis; rarely needed

If Suspecting Neuromuscular Junction Disorder

First-Line Tests

Acetylcholine receptor (AChR) antibodies: Positive in 85% of generalized myasthenia gravis; 50% of ocular myasthenia
Muscle-specific kinase (MuSK) antibodies: Positive in 40% of AChR-negative myasthenia gravis
CT chest: Thymoma present in 10-15% of myasthenia gravis; thymic hyperplasia common

Second-Line Tests

Repetitive nerve stimulation: Decremental response (more than 10% decrement) in myasthenia gravis; incremental in Lambert-Eaton
Single-fiber EMG: Most sensitive test for neuromuscular junction disorders; increased jitter
Voltage-gated calcium channel antibodies: Lambert-Eaton myasthenic syndrome; associated with small cell lung cancer
CT chest/abdomen/pelvis: Search for malignancy in Lambert-Eaton syndrome

If Suspecting Myopathy

First-Line Tests

Creatine kinase: Usually elevated (5-50× normal in inflammatory myopathy); may be normal in steroid myopathy
EMG: Myopathic pattern (small, polyphasic motor unit potentials; early recruitment)
Myositis-specific antibodies: Anti-Jo-1, anti-Mi-2, anti-SRP, anti-MDA5, anti-HMGCR

Second-Line Tests

MRI of muscles: Shows inflammation, edema, fatty replacement; guides biopsy site
Muscle biopsy: Definitive diagnosis; distinguishes inflammatory from dystrophic and metabolic myopathies
Genetic testing: Muscular dystrophies; metabolic myopathies (McArdle disease, mitochondrial)
Malignancy screening: Dermatomyositis associated with malignancy; CT chest/abdomen/pelvis; age-appropriate screening

Understanding Electrodiagnostic Studies

Nerve Conduction Studies and EMG: What They Tell You

Electrodiagnostic studies are essential for localizing and characterizing neuromuscular disease. They should be performed by an experienced neurologist or neurophysiologist.

Pattern	Nerve Conduction Studies Findings	EMG Findings	Suggests
Demyelinating neuropathy	Slowed conduction velocity; prolonged distal latency; conduction block; temporal dispersion	Neurogenic changes if axonal loss secondary	Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, Charcot-Marie-Tooth type 1
Axonal neuropathy	Reduced amplitude; relatively preserved velocity	Fibrillations, positive sharp waves; neurogenic motor unit changes	Diabetic neuropathy, toxic neuropathy, Charcot-Marie-Tooth type 2
Motor neuron disease	Normal sensory studies; reduced motor amplitudes	Widespread denervation in multiple myotomes; fasciculations	Amyotrophic lateral sclerosis, spinal muscular atrophy
Neuromuscular junction disorder	Decremental response on repetitive stimulation (myasthenia); incremental response (Lambert-Eaton)	Increased jitter on single-fiber EMG	Myasthenia gravis, Lambert-Eaton syndrome
Myopathy	Normal (or low motor amplitudes if severe)	Small, polyphasic motor unit potentials; early recruitment; fibrillations in inflammatory myopathy	Inflammatory myopathy, muscular dystrophy, metabolic myopathy

Lumbar Puncture: When and Why

Indication	Expected Findings	Clinical Context
Guillain-Barré syndrome	Elevated protein (more than 0.45 g/L); normal cell count (albuminocytologic dissociation)	May be normal in first week; do not delay treatment waiting for result
Chronic inflammatory demyelinating polyneuropathy	Elevated protein; normal or mildly elevated cells	Supports diagnosis; combined with electrodiagnostic criteria
Multiple sclerosis	Oligoclonal bands present in CSF but not serum; elevated IgG index	Supports diagnosis; not required if MRI criteria met
Infectious myelitis or encephalitis	Pleocytosis; organism-specific findings; elevated protein	Culture, viral PCR, specific antibodies based on clinical suspicion
Carcinomatous meningitis	Malignant cells on cytology; elevated protein; low glucose	May require repeated sampling; flow cytometry increases yield

Muscle Biopsy: Indications and Interpretation

When to Consider Muscle Biopsy

Suspected inflammatory myopathy with negative or non-specific antibodies
Suspected muscular dystrophy requiring histological confirmation
Metabolic myopathy (glycogen storage, mitochondrial) where specific diagnosis affects management
Inclusion body myositis (characteristic inclusions on biopsy)
When EMG shows myopathic changes but diagnosis remains unclear

Practical tip: MRI of muscles before biopsy helps identify affected but not end-stage muscles; avoid recently needled muscles (EMG artifact).

Stepwise Investigation Approach

Systematic Approach Based on Localization:

All patients: Baseline blood tests (electrolytes, CK, thyroid function, glucose, B12)
Upper motor neuron pattern: MRI brain and/or spine depending on level of signs
Lower motor neuron pattern: EMG/NCS to characterize; MRI spine if radiculopathy suspected
Neuromuscular junction: Antibodies (AChR, MuSK, VGCC); repetitive stimulation; CT chest
Myopathy: CK, EMG, myositis antibodies; MRI muscles; biopsy if diagnosis unclear
Mixed or unclear: Comprehensive electrodiagnostic study; consider motor neuron disease workup

7. Pattern Recognition and Clinical Decision-Making

Practical algorithms and decision pathways for weakness

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Sudden hemiparesis (minutes to hours)	EMERGENT	Activate stroke protocol; CT head immediately; assess for thrombolysis/thrombectomy eligibility
Rapidly ascending weakness with areflexia	EMERGENT	Admit to monitored bed; serial respiratory function tests; prepare for possible intubation
Weakness with respiratory distress or declining forced vital capacity	EMERGENT	ICU admission; prepare for mechanical ventilation if FVC less than 20 mL/kg or NIF weaker than -30 cmH2O
Bilateral leg weakness with sensory level and bladder symptoms	EMERGENT	Urgent MRI spine within hours; neurosurgical consultation if compressive lesion
Descending paralysis with bulbar onset (diplopia, dysphagia)	EMERGENT	Consider botulism; contact public health; supportive care; antitoxin if available
Known myasthenia gravis with worsening weakness or new respiratory symptoms	URGENT	Assess for myasthenic crisis; check for triggers (infection, medications); monitor respiratory function closely
Progressive proximal weakness over days with elevated creatine kinase	URGENT	Admit for evaluation; check for rhabdomyolysis; initiate workup for inflammatory myopathy
New foot drop or wrist drop without trauma	URGENT	Evaluate within days; EMG/NCS to localize; MRI if radiculopathy suspected
Chronic progressive weakness without red flags	ROUTINE	Outpatient neurological evaluation; systematic workup over weeks
Fatigue without objective weakness on examination	ROUTINE	Evaluate for systemic causes (anemia, thyroid, depression); may not require neurology referral

Step 2: Classify by Onset and Duration

Hyperacute/Acute (Minutes to Days)

Think vascular, inflammatory, or toxic

Proceed to Algorithm A

Subacute (Days to Weeks)

Think inflammatory, infectious, or compressive

Proceed to Algorithm B

Chronic (Months to Years)

Think degenerative, hereditary, or metabolic

Proceed to Algorithm C

Step 3: Follow the Appropriate Algorithm

Algorithm A: Acute Weakness (Minutes to Days)

Clinical Scenario	Most Likely Diagnosis	Action
Sudden unilateral weakness with facial droop, dysarthria	Stroke (ischemic or hemorrhagic)	CT head → if no hemorrhage and within window → consider thrombolysis/thrombectomy
Sudden unilateral weakness that resolved within 1 hour	Transient ischemic attack	CT/MRI brain; carotid imaging; cardiac evaluation; antiplatelet therapy; risk stratification
Ascending symmetric weakness with areflexia, post-infectious	Guillain-Barré syndrome	Admit; lumbar puncture; serial FVC every 4-6 hours; IVIG or plasmapheresis
Flaccid paralysis with severe hypokalemia	Hypokalemic periodic paralysis or secondary hypokalemia	Cardiac monitor; potassium replacement; investigate cause of hypokalemia
Bilateral leg weakness with back pain and sensory level	Spinal cord compression or transverse myelitis	Urgent MRI spine; if compression → neurosurgery; if myelitis → steroids after excluding infection
Weakness following tick exposure, ascending	Tick paralysis	Thorough search for tick (scalp, hairline); remove tick; rapid improvement expected

Algorithm B: Subacute Weakness (Days to Weeks)

Clinical Scenario	Most Likely Diagnosis	Action
Proximal weakness with heliotrope rash or Gottron papules	Dermatomyositis	CK; myositis antibodies; EMG; MRI muscles; biopsy; malignancy screening (CT chest/abdomen/pelvis)
Proximal weakness, elevated CK, no rash	Polymyositis or other inflammatory myopathy	Myositis antibodies; EMG; MRI muscles; muscle biopsy; exclude inclusion body myositis if older patient
Fatigable weakness, ptosis worse in evening, diplopia	Myasthenia gravis	AChR and MuSK antibodies; repetitive nerve stimulation; CT chest for thymoma
Symmetric proximal and distal weakness over more than 8 weeks, areflexia	Chronic inflammatory demyelinating polyneuropathy	EMG/NCS (demyelinating pattern); lumbar puncture (elevated protein); consider IVIG trial
Severe shoulder/arm pain followed by weakness	Brachial plexopathy (neuralgic amyotrophy)	EMG/NCS (plexus localization); MRI brachial plexus; supportive care; most recover spontaneously
Proximal leg weakness in diabetic patient with severe thigh pain	Diabetic amyotrophy (lumbosacral radiculoplexopathy)	Optimize glucose control; pain management; physical therapy; gradual recovery over months

Algorithm C: Chronic Weakness (Months to Years)

Clinical Scenario	Most Likely Diagnosis	Action
Progressive asymmetric weakness with mixed UMN and LMN signs, fasciculations	Amyotrophic lateral sclerosis	EMG (widespread denervation); MRI brain and spine (exclude mimics); refer to specialized ALS clinic
Distal weakness with pes cavus, hammer toes, onset in youth, family history	Charcot-Marie-Tooth disease	EMG/NCS; genetic testing; supportive care; orthotics; genetic counseling
Finger flexor and quadriceps weakness in patient over 50, poor response to steroids	Inclusion body myositis	CK (mildly elevated); EMG; muscle biopsy (rimmed vacuoles, inclusions); no effective disease-modifying therapy
Proximal weakness in young adult with very high CK, family history	Limb-girdle muscular dystrophy	EMG; muscle biopsy; genetic testing; cardiac evaluation; supportive care
Distal weakness with myotonia, cataracts, family history	Myotonic dystrophy	EMG (myotonic discharges); genetic testing (CTG repeat expansion); cardiac monitoring; multisystem management
Length-dependent sensorimotor neuropathy in diabetic patient	Diabetic polyneuropathy	Optimize glycemic control; EMG/NCS to confirm; treat neuropathic pain; foot care education
Gait difficulty with hand clumsiness, hyperreflexia in legs, age over 50	Cervical spondylotic myelopathy	MRI cervical spine; surgical decompression if progressive or severe

Step 4: Confirm Localization and Refine Diagnosis

Examination Findings	Localization	Key Investigations	Top Differential
Hemiparesis, hyperreflexia, Babinski, hemisensory loss	Contralateral cerebral hemisphere	CT/MRI brain	Stroke, tumor, demyelination
Quadriparesis with sensory level, hyperreflexia below level	Cervical spinal cord	MRI cervical spine	Compression, myelitis, demyelination
Paraparesis with sensory level, upper motor neuron signs in legs	Thoracic spinal cord	MRI thoracic spine	Compression, transverse myelitis
Asymmetric weakness with atrophy, fasciculations, hyperreflexia	Upper and lower motor neurons (diffuse)	EMG; MRI brain and spine	Motor neuron disease (ALS)
Radicular pattern weakness with dermatomal sensory loss	Nerve root	MRI spine; EMG	Disc herniation, foraminal stenosis
Distal symmetric weakness with stocking-glove sensory loss, areflexia	Peripheral nerves (polyneuropathy)	EMG/NCS; metabolic workup	Diabetic, toxic, inflammatory neuropathy
Fatigable weakness, ptosis, diplopia, normal reflexes	Neuromuscular junction	AChR/MuSK antibodies; repetitive stimulation	Myasthenia gravis
Proximal symmetric weakness, no sensory loss, normal or reduced reflexes	Muscle	CK; EMG; muscle biopsy	Inflammatory myopathy, muscular dystrophy

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Patient with Guillain-Barré syndrome has FVC less than 1.5 L	Prepare for intubation; transfer to ICU	Continue IVIG or plasmapheresis; monitor for dysautonomia
Myasthenia patient cannot swallow safely	NPO status; nasogastric tube; assess for crisis	IVIG or plasmapheresis; avoid aminoglycosides and other contraindicated medications
CK is more than 10,000 U/L with weakness	IV fluids; monitor renal function; check for myoglobinuria	Investigate cause (inflammatory myopathy, rhabdomyolysis, statin toxicity)
Patient on statin develops weakness	Check CK; stop statin if significantly elevated	Monitor for improvement; check HMGCR antibodies if weakness persists (immune-mediated necrotizing myopathy)
Suspected spinal cord compression with bladder symptoms	Urgent MRI spine (within hours); dexamethasone if malignancy suspected	Neurosurgical or oncological consultation based on findings
AChR and MuSK antibodies are negative but myasthenia suspected	Proceed with repetitive nerve stimulation and single-fiber EMG	Consider seronegative myasthenia; trial of pyridostigmine; LRP4 antibodies if available
EMG shows widespread denervation in patient with weakness	MRI brain and full spine to exclude structural cause	If imaging negative and clinical picture fits, diagnose motor neuron disease; refer to specialist clinic
Young patient with proximal weakness and family history of muscular dystrophy	Check CK; arrange genetic testing	Cardiac evaluation (many dystrophies affect heart); genetic counseling; multidisciplinary care

Troubleshooting: Weakness Not Responding to Treatment

Ask These Questions

Is the diagnosis correct? — Revisit localization; consider repeating EMG; review biopsy
Is there a second diagnosis? — Patients can have overlapping conditions (for example: myasthenia plus thyroid disease)
Was treatment adequate? — Duration and dose of immunotherapy; compliance
Is this a treatment-resistant condition? — Inclusion body myositis does not respond to immunosuppression
Are there complicating factors? — Infection, medication side effects, deconditioning
Is the weakness functional? — Consider if inconsistencies on examination; psychiatric evaluation if appropriate

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

Localization before diagnosis: The most important step in evaluating weakness is determining WHERE the lesion is (upper motor neuron, lower motor neuron, neuromuscular junction, or muscle) before considering WHAT the lesion is.

Mixed upper and lower motor neuron signs = motor neuron disease until proven otherwise: Finding both hyperreflexia AND atrophy/fasciculations in the same limb is the hallmark of amyotrophic lateral sclerosis.

Respiratory monitoring saves lives in Guillain-Barré syndrome: Serial forced vital capacity measurements are more important than any other test. Intubate when FVC falls below 20 mL/kg, not when the patient becomes hypoxic.

Neck flexion strength correlates with respiratory function: A patient who cannot lift their head off the pillow likely has significant diaphragmatic weakness. Use this as a rapid bedside screen.

Think Lambert-Eaton in proximal weakness with autonomic symptoms: Dry mouth, constipation, and erectile dysfunction combined with proximal weakness that briefly improves with exercise should prompt evaluation for Lambert-Eaton syndrome and underlying malignancy.

Check the medication list: Statins, corticosteroids, colchicine, and immune checkpoint inhibitors are common causes of weakness. A thorough medication history may reveal the diagnosis immediately.

Inclusion body myositis has a distinctive pattern: Weakness of finger flexors and quadriceps in a patient over 50 that does not respond to immunosuppression is classic for inclusion body myositis. Early recognition prevents futile treatment.

Sensory involvement helps localize: Weakness WITH sensory loss suggests peripheral nerve, plexus, root, or spinal cord involvement. Weakness WITHOUT sensory loss suggests anterior horn cell, neuromuscular junction, or muscle.

Critical Pitfalls to Avoid

Confusing fatigue with weakness: Many patients say “weak” when they mean “tired.” Always verify objective weakness on examination. Fatigue without objective weakness has a different differential (anemia, depression, hypothyroidism, chronic fatigue syndrome).

Assuming normal oxygen saturation means adequate ventilation: In neuromuscular respiratory failure, hypercapnia (elevated CO2) occurs before hypoxia. A normal oxygen saturation does not exclude impending respiratory failure. Check arterial blood gas and FVC.

Missing spinal cord compression because of incomplete examination: Always check for a sensory level in patients with bilateral leg weakness. A sensory level indicates spinal cord pathology and requires urgent MRI. Missing cord compression can result in permanent paralysis.

Delaying treatment of Guillain-Barré syndrome for lumbar puncture results: The lumbar puncture may be normal in the first week. If the clinical picture is consistent, start IVIG or plasmapheresis without waiting for cerebrospinal fluid results.

Giving contraindicated medications in myasthenia gravis: Aminoglycosides, fluoroquinolones, magnesium, beta-blockers, and many other drugs can precipitate myasthenic crisis. Always check medication safety before prescribing to patients with myasthenia gravis.

Forgetting to screen for malignancy in dermatomyositis and Lambert-Eaton syndrome: Up to 30% of dermatomyositis cases and 50-60% of Lambert-Eaton cases are paraneoplastic. Age-appropriate cancer screening plus CT of chest, abdomen, and pelvis is essential.

Attributing all weakness to “old age” or deconditioning: Progressive weakness always has a cause. Elderly patients can develop motor neuron disease, myasthenia gravis, or inflammatory myopathy. Do not dismiss weakness as inevitable aging.

Stopping statins too briefly before concluding they are not the cause: Statin-induced myopathy may take weeks to months to resolve after stopping. Additionally, immune-mediated necrotizing myopathy triggered by statins persists even after drug discontinuation and requires immunosuppression.

Key Takeaways

Distinguish true weakness from fatigue: True weakness is objective reduction in strength; fatigue is subjective sense of tiredness without objective weakness. This distinction fundamentally changes the differential.
Localization is paramount: Determine if the lesion is upper motor neuron, lower motor neuron, neuromuscular junction, or muscle BEFORE ordering investigations. The localization drives the entire workup.
Time course guides urgency: Hyperacute onset suggests stroke; acute ascending weakness suggests Guillain-Barré; subacute proximal weakness suggests inflammatory myopathy; chronic progressive weakness suggests degenerative or hereditary disease.
Upper motor neuron lesions produce spasticity and hyperreflexia: But these may be absent acutely (spinal shock). Babinski sign and pyramidal distribution of weakness help identify upper motor neuron pathology.
Lower motor neuron lesions produce flaccidity, atrophy, and fasciculations: Hyporeflexia or areflexia is typical. The pattern (dermatomal, peripheral nerve, diffuse) helps localize within the lower motor neuron pathway.
Neuromuscular junction disorders cause fatigable weakness: Symptoms fluctuate through the day, worsen with activity, and improve with rest. Ocular and bulbar involvement is common in myasthenia gravis.
Myopathies cause proximal weakness without sensory loss: Creatine kinase is usually elevated. The pattern of weakness, associated features (rash, myotonia), and family history guide specific diagnosis.
Red flags require immediate action: Respiratory compromise, acute cord compression, and stroke are emergencies. Respiratory monitoring is critical in Guillain-Barré syndrome and myasthenic crisis.
Always consider drug-induced causes: Statins, corticosteroids, and many other medications cause weakness. Review the medication list early in the evaluation.
Do not forget paraneoplastic causes: Dermatomyositis, Lambert-Eaton syndrome, and some neuropathies may be the first manifestation of occult malignancy. Appropriate cancer screening is essential.

Quick Reference Algorithm

Systematic Approach to Weakness:

Confirm true weakness: Distinguish from fatigue, pain-limited movement, or other mimics by objective strength testing.
Identify red flags: Respiratory involvement, acute onset, spinal cord features, and bulbar symptoms require immediate action.
Localize anatomically: Upper motor neuron, lower motor neuron, neuromuscular junction, or muscle based on examination findings.
Characterize the pattern: Proximal versus distal, symmetric versus asymmetric, acute versus chronic.
Order appropriate investigations: Baseline bloods for all; imaging, electrodiagnostics, and specialized tests guided by localization.
Consider common and serious diagnoses: Use probability-based thinking but do not miss rare treatable conditions.
Review medications and exposures: Drug-induced weakness is common and reversible.
Initiate treatment and monitor response: Many causes of weakness are treatable; response to therapy may confirm the diagnosis.